Combined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia

European Heart Journal

Volumn 24, Issue 8, 2003, Pages 685-689

  Shepherd, James ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A; ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ABSORPTION; BINDING AFFINITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIGESTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; INTERMETHOD COMPARISON; LIPID METABOLISM; LIPID TRANSPORT; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; AZETIDINES; CHOLESTEROL; DRUG THERAPY, COMBINATION; HUMANS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION;

EID: 0037395504     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(03)00085-X     Document Type: Editorial

References (16)

1. Shepherd J. Lipoprotein metabolism: an overview. Ann Acad Med Singapore 1992;21:106-13.
2. van Heck M, France CF, Compton DS et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH 58235, in the rat and rhesus monkey though the identification of the active metabolites of SCH 48461. J Pharmacol Exp Ther 1997;283:157-63.
3. Zhu Y, Statkevich P, Kosogiou T et al. Effect of ezetimibe (SCH 58235) on the activity of drug metabolising enzymes in vivo. Clin Pharmacol Ther 2000;67:152.
4. Goldberg PB, Roberts J. Pharmacologic basis for developing rational drug regimens for elderly patients. Med Clin North Am 1983;67:315-21.
5. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114:956-66.
6. Shepherd J. The Statin Era in cardiovascular medicine. Cardiovasc Rev Rep 2001;22:639-48.
7. Hoerger TJ, Bala MV, Bray JW et al. Treatment patterns and distribution of low density lipoprotein cholesterol levels in treatment - eligible vs adults. Am J Cardiol 1998;82: 61-5.
8. Frolkis JP, Zyzanski SJ, Schwartz JM et al. Physician noncompliance with the 1993 National Cholesterol Education Program Guidelines. Circulation 1998;98:851-5.
9. Euroaspire I and II Study Group. Clinical reality of coronary prevention guidelines: a comparison of Euroaspire I and II in nine countries. Lancet 2001;357:995-1001.
10. Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in 668 patients with primary hyperchotesterolemia. J Am Coll Cardiol 2002; 39:226A-7A.
11. Ballantyne C, Houri J, Notarbartolo A et al. Ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. J Am Coll Cordial 2002; 39:227A.
12. Lipka L, Kerzner B, Corbelli J et al. Ezetimibe coadministered with Lovastatin in patients with primary hypercholesterolemia. J Am Coll Cordial 2002;39:430B.
13. Wood D, de Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Eur Heart J 1998; 19:1434-503.
14. Buchwald H, Matts JP, Fitch LL et al. Changes in sequential coronary arteriograms and subsequent coronary events. POSCH group. JAMA 1992;268:1429-33.
15. White CW, Gabel FL, Campeau L et al. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation 2001; 104:2660-5.
16. Taylor AJ, Kent SM, Flaherty PJ et al. ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol. Circulation 2002;106:2055-60.